Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Next Previous
Trial Profile

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS-1003 (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Leiomyosarcoma; Lymphoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors CStone Pharmaceuticals

    • Most Recent Events

    • 20 Sep 2019 According to a CStone Pharmaceuticals media release, preliminary data (n=19, as of 15th Jun 2019) from this phase I bridging study were presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019 CSCO Annual Meeting).
    • 20 Sep 2019 Preliminary data (n=19, as of 15th Jun 2019) from this phase I bridging study presented in a CStone Pharmaceuticals media release.
    • 22 Aug 2019 According to a CStone Pharmaceuticals media release, the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019) has accepted an abstract of this trial and the results will be released in oral presentation at the 2019 CSCO Annual Meeting which includes preliminary safety, pharmacokinetics and efficacy results from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top